Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia
- PMID: 33956869
- PMCID: PMC8101714
- DOI: 10.1371/journal.pone.0251234
Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic, including Indonesia. However, there are only limited data regarding the precise prevalence of the COVID-19 pandemic in Indonesia. Here, to estimate the magnitude of SARS-CoV-2 infection in East Java, Indonesia, we investigated the prevalence of immunoglobulin G (IgG) antibodies. We enrolled 1,819 individuals from June to December 2020 and observed that the subjects' overall prevalence of IgG antibody to SARS-CoV-2 was 11.4% (207/1,819). The prevalence of anti-SARS-CoV-2 antibodies differed significantly between the job/occupation groups (P = 0.0001). A greater prevalence of IgG was detected in laboratory technicians (who take samples from suspected cases and deal with polymerase chain reaction [PCR] procedures, 22.2%) compared to medical personnel who see and take direct care of patients with COVID-19 (e.g., physicians and nurses, 6.0%), other staff in medical facilities (2.9%), general population (12.1%) and non-COVID-19 patients (14.6%). The highest prevalence among age groups was in the 40-49-year-olds (14.8%), and the lowest prevalence was in the 20-29-year-olds (7.4%). However, the younger population still showed a higher prevalence than generally reported, suggesting greater exposure to the virus but less susceptibility to the disease. A geographical difference was also observed: a higher prevalence in Surabaya (13.1%) than in Jombang (9.9%). In conclusion, the COVID-19 outbreak among asymptomatic populations was characterized by a high prevalence of infection in East Java, Indonesia.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.Clin Microbiol Infect. 2021 Mar;27(3):470.e1-470.e9. doi: 10.1016/j.cmi.2020.11.009. Epub 2020 Nov 20. Clin Microbiol Infect. 2021. PMID: 33221432 Free PMC article.
-
Seroprevalence of SARS-CoV-2 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java, Indonesia.PeerJ. 2023 Sep 25;11:e16142. doi: 10.7717/peerj.16142. eCollection 2023. PeerJ. 2023. PMID: 37780375 Free PMC article.
-
Prevalence of SARS-COV-2 positivity in 516 German intensive care and emergency physicians studied by seroprevalence of antibodies National Covid Survey Germany (NAT-COV-SURV).PLoS One. 2021 Apr 8;16(4):e0248813. doi: 10.1371/journal.pone.0248813. eCollection 2021. PLoS One. 2021. PMID: 33831032 Free PMC article. Clinical Trial.
-
Seroprevalence of Immunoglobulin M and G Antibodies against SARS-CoV-2 Virus: A Systematic Review and Meta-Analysis Study.Iran J Immunol. 2021 Mar;18(1):34-46. doi: 10.22034/iji.2021.87723.1824. Iran J Immunol. 2021. PMID: 33787512
-
[The prevalence rate of anti-SARS-CoV-2-IgG is 1.2% - Screening in asymptomatic outpatients in Germany (Northrhine-Westfalia)].MMW Fortschr Med. 2020 Aug;162(14):44-46. doi: 10.1007/s15006-020-0750-y. MMW Fortschr Med. 2020. PMID: 32780376 Free PMC article. Review. German.
Cited by
-
Pre-vaccination seroprevalence of SARS-CoV-2 antibodies in the Volta Region, Ghana.IJID Reg. 2024 Jan 20;10:179-182. doi: 10.1016/j.ijregi.2024.01.007. eCollection 2024 Mar. IJID Reg. 2024. PMID: 38328557 Free PMC article.
-
Factors Associated with Vaccine Breakthrough Incidence among Health Care Workers Vaccinated with Inactivated SARS-CoV2 Vaccine (CoronaVac).J Res Health Sci. 2022 Jun 30;22(2):e00551. doi: 10.34172/jrhs.2022.86. J Res Health Sci. 2022. PMID: 36511263 Free PMC article.
-
Cytokine profiles of mild-to-moderate SARS-CoV-2 infected and recovered pre-vaccinated individuals residing in Indonesia.PeerJ. 2024 Apr 18;12:e17257. doi: 10.7717/peerj.17257. eCollection 2024. PeerJ. 2024. PMID: 38646483 Free PMC article.
-
Clinico-Epidemiological Laboratory Findings of COVID- 19 Positive Patients in a Hospital in Saudi Arabia.Infect Drug Resist. 2023 Jul 25;16:4845-4856. doi: 10.2147/IDR.S418629. eCollection 2023. Infect Drug Resist. 2023. PMID: 37520449 Free PMC article.
-
Serological surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity to SARS-CoV-2 during an outbreak in Dili, Timor-Leste.Int J Infect Dis. 2022 Jun;119:80-86. doi: 10.1016/j.ijid.2022.03.043. Epub 2022 Mar 28. Int J Infect Dis. 2022. PMID: 35358723 Free PMC article.
References
-
- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health Organization; 2021. [cited 2021 March 1]. Available from: https://covid19.who.int/
-
- Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al.. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34: 101623. 10.1016/j.tmaid.2020.101623 - DOI - PMC - PubMed
-
- World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection. Geneva: World Health Organization; 2020. March 17 [cited 2021 March 1]. Available from: https://apps.who.int/iris/handle/10665/331656
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous